YOKNEAM, Israel, Jan. 3, 2023 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced that Moshe Mizrahy, Chairman and Chief Executive Officer, Yair Malca, Chief Financial Officer and Spero Theodorou MD, Chief Medical Officer, will present virtually at the 25th Annual Needham Growth Conference on Jan. 12, 2023.
The fireside chat, moderated by Mike Matson, Senior Research Analyst, is scheduled for 10:15 am Eastern Time on Thursday, Jan. 12 and will be webcast from InMode's Investor Relations website at https://inmodemd.com/investors/. InMode will also hold one-on-one investor meetings in person on Wednesday, Jan. 11 and virtual meetings on Thursday, Jan. 12. To schedule a meeting, please contact your Needham representative.
For more information about the event, visit InMode's investor relations site here.
About InMode
InMode is a leading global provider of innovative medical technologies. InMode develops, manufactures, and markets devices harnessing novel radiofrequency ("RF") technology. InMode strives to enable new emerging surgical procedures as well as improve existing treatments. InMode has leveraged its medically accepted minimally invasive RF technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. For more information about InMode, please visit www.inmodemd.com.
Investor Relations Contact:
Miri Segal-Scharia
MS-IR LLC
This email address is being protected from spambots. You need JavaScript enabled to view it.
+ 917-607-8654
Last Trade: | US$14.59 |
Daily Change: | -0.35 -2.34 |
Daily Volume: | 195,971 |
Market Cap: | US$922.230M |
September 02, 2025 July 30, 2025 April 28, 2025 |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load